Effectiveness of Umonium<sup>38</sup> against Burkholderia pseudomallei, Escherichia coli, Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus (MRSA)

dc.contributor.authorRuanchaiman S.
dc.contributor.authorAmornchai P.
dc.contributor.authorWuthiekanun V.
dc.contributor.authorLangla S.
dc.contributor.authorMaroongruang P.
dc.contributor.authorLe K.K.
dc.contributor.authorBlacksell S.D.
dc.contributor.correspondenceRuanchaiman S.
dc.contributor.otherMahidol University
dc.date.accessioned2024-02-27T18:12:32Z
dc.date.available2024-02-27T18:12:32Z
dc.date.issued2024-02-16
dc.description.abstractAIMS: We investigated the antibacterial efficacy of Umonium38 and Virkon® against Burkholderia pseudomallei, Escherichia coli, Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus (MRSA) up to 14 days following treatment. METHODS AND RESULTS: Umonium38 was diluted to 0.5%, 1.0%, 1.5%, 2.0%, 2.5% and 3%, tested against the bacterial strains at various contact times (15 min to 24 h), and incubated for up to 14 days. A minimum concentration of 0.5% Umonium38 with a contact time of 15 min effectively killed approximately 108 CFU/ml of all four bacterial species. No growth was observed on agar plates from day 0 until day 14 for all six concentrations. The bacteria were also inactivated by a 30-minute treatment time using Virkon® 1% solution. CONCLUSIONS: Umonium38 effectively inactivates B. pseudomallei, E. coli, P. aeruginosa and MRSA at a concentration of ≥ 0.5% with a contact time of at least 15 min. The antimicrobial effect of Umonium38 remained for 14 days.
dc.identifier.citationBMC infectious diseases Vol.24 No.1 (2024) , 212
dc.identifier.doi10.1186/s12879-024-09102-9
dc.identifier.eissn14712334
dc.identifier.pmid38365598
dc.identifier.scopus2-s2.0-85185404624
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/97353
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleEffectiveness of Umonium<sup>38</sup> against Burkholderia pseudomallei, Escherichia coli, Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus (MRSA)
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85185404624&origin=inward
oaire.citation.issue1
oaire.citation.titleBMC infectious diseases
oaire.citation.volume24
oairecerif.author.affiliationMahidol Oxford Tropical Medicine Research Unit
oairecerif.author.affiliationNuffield Department of Medicine

Files

Collections